

Three Historic Tsunamis and How to Ride Them

Erez Kalir | Porter & Co. Tech Frontiers Lead Analyst



Technological "tsunamis"



In every human lifetime, we encounter a small handful of **tsunamis**, the proverbial **100- foot-tall waves** that **change everything** . . . Across technology, economics, culture.

The thing about these tsunamis is – if you're relatively early to them, understand what they're about, and are able to identify the right financial instruments to ride them, you can earn **generational wealth**. For example, investing \$1 million into a basket of Amazon, Google, Microsoft and Apple in 2003 would have generated \$50 million today.

Another thing about these tsunamis is, they're not only about generating wealth, but also about understanding the world we live in as it changes. There aren't many sectors of the stock market where novel developments are going to change how human beings live. This isn't true, for instance, about property-and-casualty insurance of financial services. But it's true about technology.

We are living amid three epic technological tsunamis today



Artificial Intelligence is transforming how we work

Blockchain is transforming money, and how we bank and transact

Biotech is transforming how we approach health and disease



Artificial Intelligence is transforming how we work

Blockchain is transforming money, and how we bank and transact

Biotech is transforming how we approach health and disease



Al is gaining adoption faster than any technology in recorded history . . .

Facebook reached 100 million users in 4 years, 6 months


Instagram reached 100 million users in 2 years, 4 months

ChatGPT reached 100 million users in 2 months

... and Chinese AI knock-off **DeepSeek** reached 100 million users in **7 days**



The scale of investment in AI has very few precedents . . .



Four Big Tech Firms (Alphabet, Amazon, Meta, and Microsoft) will spend \$365b+ on AI CapEx in 2025

This is more than the entire global pharma industry spends annually on R&D (\$240b)

It's also 3x Apple's total R&D spend over the past decade

CHART: THE ECONOMIST



Al's biggest impact will be on employment and work...

The Great Human Replacement: How Al Will Create the Largest Political Crisis Since the Industrial Revolution

Here's what my models predict for the next three years:

- Accounting and bookkeeping: 78% job displacement by 2027
- Legal research and document review: 84% replacement rate
- Financial analysis roles: 71% automation potential
- Marketing and advertising: 62% algorithmic takeover
- Customer service: 89% Al replacement (already happening)

That's roughly 47 million jobs in the United States alone.



Al can now do in a few minutes what until recently would have been a day's work for a junior investment banker or consultant at Goldman Sachs or McKinsey


Good evening Claude. Could you please build me a DCF financial model for the public company Marketwise, which estimates the value of the company's stock using a reasonable set of assumptions for your model?





We already see evidence of Al's impact on the job market ...

UK Jobs Slowdown Is Concentrated in Al-Exposed Roles



Source: Office for National Statistics; Department for Education; McKinsey



One of the best ways to play the explosion of AI is to focus on "picks & shovels"...


Case study: Al data centers



- The world will spend approximately \$6 trillion on AI data centers over the coming 5 years
- Approximately \$1 trillion of this investment will happen in China
- The player best positioned to benefit from this boom has a US ADR that could plausibly appreciate ~10x+



Another way is to focus on how governments are likely to respond to Al's impact...



Hold your gold and keep your (bit)coins – but we've also got something better for you




Artificial Intelligence is transforming how we work

Blockchain is transforming money, and how we bank and transact

Biotech is transforming how we approach health and disease



Adoption of cryptocurrencies is outpacing early Internet adoption . . .





The GENIUS Act is poised to supercharge institutional blockchain adoption . . .

GENIUS Act provision	Barrier it removes	Institutional impact		
Defines "payment stablecoins," sets who can issue them, and treats permitted payment stablecoins as not securities.	Regulatory ambiguity over asset classification and SEC registration risk.	Broker-dealers, exchanges, funds, and custodians get a clear, tradable instrument for payments/settlement.		
Requires 100% reserve backing in cash or short-term Treasuries and monthly public reserve disclosures.	Counterparty/run-risk and transparency concerns for risk committees.	Greater comfort for corporate treasuries; stablecoins become acceptable cash-managemen and settlement rails.		
Subjects permitted issuers to BSA/AML; allows trading/custody through regulated brokers, exchanges, and ATS.	Compliance/custody uncertainty and limited institutional access points.	Banks and brokers can integrate within existing compliance programs; easier onboarding for institutional clients.		
Allows foreign issuers access via a "comparability" determination; extends U.S. oversight to foreign stablecoins.	Cross-border fragmentation and uneven standards across jurisdictions.	Larger, more liquid global stablecoin markets usable by multinationals for payments and treasury.		
Directs agencies to issue implementing rules on a set clock (e.g., ~180 days) and creates a unified federal/state regime.	Patchwork rules and slow timelines that stall product launches.	Predictable, near-term path for compliant products; accelerates institutional pilots and listings.		
Policy alignment: dollar-backed coins with T-bill reserves, transparency, and prudential oversight.	Concerns about policy support and macro implications of USD stablecoins.	Legitimizes dollar-stable settlement assets; catalyzes bank participation and broader institutional use.		



In the not distant future . . .

Every meaningful economic exchange will be paid for with a digital currency or token, transacted through a smart contract, and recorded on the blockchain.

- ... Buying a car
- ... Selling a house
- ... Paying and receiving wages
- ... Buying and selling stock
- ... Intergenerational wealth transfer



The prudent way to approach the shift to blockchain is to build a Blue Chip, "Forever" portfolio . . .

Porter Stansberry's Permanent Portfolio

The Lindy Forever Companies						
	Ticker	Segment Allocation	Portfolio Allocation	Price per Share	Position Value	Number of Shares
Philip Morris International	PM	15%	3.75%	\$121.69	\$37,500	308
Coca-Cola	КО	15%	3.75%	\$71.45	\$37,500	525
McDonald's	MCD	15%	3.75%	\$300.47	\$37,500	125
ohnson & Johnson	JNJ	10%	2.50%	\$160.60	\$25,000	156
Caterpillar	CAT	10%	2.50%	\$378.25	\$25,000	66
Deere & Company	DE	10%	2.50%	\$406.93	\$25,000	61
EQT	EQT	5%	1.25%	\$35.16	\$12,500	356
Texas Pacific Land	TPL	5%	1.25%	\$927.73	\$12,500	13
Taiwan Semiconductor	TSM	5%	1.25%	\$182.35	\$12,500	69
Alibaba	BABA	5%	1.25%	\$95.46	\$12,500	131
Tencent	TCEHY	5%	1.25%	\$52.40	\$12,500	239
The Lindy Forever Companies			25.00%		\$250,000	

We will build the equivalent of this Forever Portfolio at Tech Frontiers:
The Blockchain Blue Chips Portfolio



Artificial Intelligence is transforming how we work

Blockchain is transforming money, and how we bank and transact

Biotech is transforming how we approach health and disease



Al's application to medicine will enable us to predict individual disease risk much earlier

nature

This AI tool predicts your risk of 1,000 diseases — by looking at your medical records

A new artificial intelligence (AI) tool can forecast a person's risk of developing more than 1,000 diseases, in some cases providing a prediction decades in advance. The model, called Delphi-2M, uses health records and lifestyle factors to estimate the likelihood a person will develop diseases such as cancer, skin diseases and immune conditions head of time. Although Delphi-2M was trained only on one data set from the United Kingdom, its multi-disease modeling could one day help clinicians to identify high-risk people, allowing for the early roll-out of preventive measures. The model is described in <a href="https://example.com/astarch-com/up to 20 years ahead of time. Although Delphi-2M, was trained only on one data set from the United Kingdom, its multi-disease modeling could one day help clinicians to identify high-risk people, allowing for the early roll-out of preventive measures. The model is described in <a href="https://example.com/astarch-com/up to 20 years ahead of time. Although Delphi-2M, was trained only on one data set from the United Kingdom, its multi-disease modeling could one day help clinicians to identify high-risk people, allowing for the early roll-out of preventive measures. The model is described in <a href="https://example.com/astarch-c



While new treatment modalities – such as siRNA – while allow us to treat previously "undruggable" diseases

Top 10 Medicines by Sales and Category

Rank	Drug	2024 revenue (US\$B)	Category	Main indication(s)
1	Keytruda (pembrolizumab)	29.5	mAb	Cancer (multiple tumor types)
2	Eliquis (apixaban)	20.7	Small molecule	Anticoagulant (atrial fibrillation, DVT/PE)
3	Ozempic (semaglutide)	18.7	Small molecule	Type 2 diabetes, weight management
4	Dupixent (dupilumab)	15.1	mAb	Atopic dermatitis, asthma, COPD, eosinophilic esophagitis
5	Biktarvy (bictegravir/FTC/TAF)	13.4	Small molecule	HIV
6	Jardiance family (empagliflozin ± combos)	13.0	Small molecule	Type 2 diabetes, heart failure, CKD
7	Skyrizi (risankizumab)	11.7	mAb	Psoriasis, Crohn's disease, ulcerative colitis
8	Darzalex (daratumumab)	11.7	mAb	Multiple myeloma
9	Mounjaro (tirzepatide)	11.5	Small molecule	Type 2 diabetes, obesity/weight management
10	Stelara (ustekinumab)	10.4	mAb	Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis

- The world's top 10 bestselling medicines today are all either mAbs or small molecules
- mAbs were first created 50 years ago while small molecules date to the late 19th Century
- Within a decade, siRNA's and other Genetic Medicines will crack this list



The current Bear Market in biotech creates an extraordinary, quite possibly once-in-a-lifetime opportunity: The chance to buy the most promising early-stage life sciences companies with "value investing" style Margin of Safety

TECHF	TECHFRONTIERS PORTFOLIO						
						≚ Export to CSV	
Ticker		Company	Entry D 📤	Entry Price	Price	Total Return	Status
Biotech							
SGMT	Ø	Sagimet Biosciences	01/09/2024	\$5.71	\$6.73	86.22%	Buy Up to \$5.00*
ROIV	(e)	Roivant Sciences	02/29/2024	\$11.44	\$14.74	28.85%	Hold
TGTX	&	TG Therapeutics	07/03/2024	\$18.79	\$35.57	103.19%	Hold^^
SGMT	&	Sagimet Biosciences	09/05/2024	\$2.62	\$6.73	138.17%	Buy Up to \$5.00***
BCYC		Bicycle Therapeutics	05/07/2025	\$7.78	\$7.09	-8.87%	Buy Up to \$8.75
ACET		Adicet Bio	05/07/2025	\$0.49	\$0.83	69.31%	Buy Up to \$0.75
ALNY	&	Alnylam Pharmaceuticals	06/04/2025	\$305.31	\$454.41	48.84%	Buy Up to \$320
PRME		Prime Medicine	07/02/2025	\$3.07	\$5.39	75.57%	Buy Up to \$4.00
FBIO		Fortress Biotech	09/03/2025	\$2.95	\$3.65	23.73%	Buy Up to \$3.45
Toeholds							
8473:JP		SBI Holdings	02/05/2025	¥4,315.00	¥6,526.00	54.48%	Buy Up to ¥7,200^

What's coming at Tech Frontiers



We will cover in depth each of these historic "tsunamis" – and help you identify the securities to ride them with favorably asymmetric risk/reward

We will "connect the dots" between these epic tsunamis and what's unfolding in the Big Picture of our economy and markets

Alongside our investment recommendations, we'll bring you interviews with some of the smartest people we know – Nobel laureate scientists and world-class investors

Thank you for subscribing!